Mucopolysaccharidosis (MPS) physical symptom score: Development, reliability, and validity

JIMD Reports

Volumn 26, Issue , 2016, Pages 61-68

  Ahmed, A ^a   Rudser, K ^b   Kunin Batson, A ^a   Delaney, K ^a   Whitley, C ^a   Shapiro, E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Carpal tunnel syndrome; Disease burden; Enzyme replacement therapy; Hematopoietic cell transplant; Shunt placement

Indexed keywords

EID: 84962409290     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2015_485     Document Type: Chapter

References (26)

1. Ahmed A, Whitley CB, Cooksley R et al (2014a) Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the alpha-L-iduronidase gene in Hurler-Scheie syndrome. Mol Genet Metab 111(2):123–127
2. Ahmed A, Kunin-Batson A, Redtree E, Whitley C, Shapiro E (2014b) MPS (mucopolysaccharidosis) specific physical symptom score – development, reliability and validity. Mol Genet Metab 111(2): S17–S18
3. Beesley CE, Meaney CA, Greenland G et al (2001) Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet 109: 503–511
4. Bertola F, Filocamo M, Casati G et al (2011) IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel ∝-L-iduronidase (IDUA) alleles. Hum Mutat 32(6): 189–210
5. Clarke LA, Heppner J (2002) Mucopolysaccharidosis Type I, (Updated 2011 Jul 21). In: Pagon RA, Adam MP, Bird TD et al (eds) Gene Reviews™ [Internet]. University of Washington, Seattle. 1993–2013. http://www.ncbi.nlm.nih.gov/books/NBK1162/
6. R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. http://www.R-project.org/
7. D’Aco K, Underhill L, Rangachari L et al (2012) Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr 171:911–919
8. Diggle P, Heagerty P, Liang K, Zeger S (2002) Analysis of longitudinal data. Oxford University Press, New York
9. Haley SM, Fragala-Pinkham MA, Dumas HM, Ni P, Skrinar AM, Cox GF (2006) A physical performance measure for individuals with mucopolysaccharidosis type I. Dev Med Child Neurol 48: 576–581
10. Hopwood JJ, Morris CP (1990) The mucopolysaccharidosis: diagnosis, molecular genetics and treatment. Mol Biol Med 7(5): 381–404
11. Kakkis ED, Muenzer J, Tiller GE et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344:182–188
12. Landgraf JM, Abetz L, Ware JE (1996) The CHQ user’s manual, 1st edn. The Health Institute, New England Medical Center, Boston
13. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254
14. Moore D, Connock MJ, Wraith JE, Lavery C (2008) The prevalence of and survival in mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis 3: 24
15. Muenzer J, Wraith JE, Clarke LA (2009) Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 123:19–29
16. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, Valle D, Childs R, Kinzler K (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3421–3452
17. Pastores GM, Arn P, Beck M et al (2007) The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab 91:37–47
18. Peters C, Balthazor M, Shapiro E et al (1996) Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 87:4894–4902
19. Peters C, Shapiro E, Anderson J et al (1998) Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 91:2601–2608
20. Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ (1995) Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat 6:288–302
21. Souillet G, GuVon N, Maire I et al (2003) Outcome of 27 patients with Hurler’s syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 31: 1105–1117
22. Sparrow SS, Cicchetti DV, Balla DA (2005) Vineland Adaptive Behavior Scales. 2nd Edition. Psychological Corporation, San Antonio
23. Staba SL, Escolar ML, Poe M et al (2004) Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. N Engl J Med 350:1960–1969
24. Terlato NJ, Cox GF (2003) Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literature. Genet Med 5:286–294
25. Wraith JE, Clarke LA, Beck M et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144:581–588
26. Yund B, Rudser K, Ahmed A et al (2015) Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II. Mol Genet Metab 114(2):170–177